Global Respiratory Inhalers Market Size, Share, and COVID-19 Impact Analysis, By Type (Dry Powdered Inhalers, Metered Dose Inhalers), By Indication (Asthma, COPD), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-use (Hospitals, Homecare Settings, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030Industry: Healthcare
Global Respiratory Inhalers Market Insights Forecasts to 2030
- The Respiratory Inhalers Market Size was valued at USD 13.4 Billion in 2021.
- The Market is Growing at a CAGR of 20.2% from 2021 to 2030
- The Worldwide Respiratory Inhalers Market is expected to reach USD 54.1 Billion by 2030
- Asia Pacific is expected To Grow the fastest during the forecast period
Get more details on this report -
The global Respiratory Inhalers Market is expected to reach USD 54.1 Billion by 2030, at a CAGR of 20.2% during the forecast period 2021 to 2030.
Respiratory inhalers are basically used by the patient to inhale medicines that are crucial for the treatment of chronic lung issues. There are various products which should be taken by the patients directly to the airways like inhalers, dry powder inhalers, Nebulizers, metered dose inhalers, and soft mist inhalers.
Impact of COVID 19 on Respiratory Inhalers Market
As per the World Health Organization (WHO), about 262 million people across the world suffered from asthma in the year 2019 that is one of the major non communicable diseases which affects children and adults. Apart from this, the rising prevalence of chronic obstructive pulmonary disease (COPD) has resulted into 3.23 million deaths across the globe. With the onset of COVID 19 pandemic, the entire global supply chain was drastically affected. Many industries have see shortage of product inventories which has resulted into problems in clinical testing, post approval activities, and regulatory procedures. Having said that the market is going to witness a positive growth after the pandemic because key market players are planning to come up with advanced products to treat respiratory problems. Furthermore, COVID 19 has led to the increasing demand for cutting edge digital devices as well as solutions for respiratory care.
Global Respiratory Inhalers Market Report Coverage
|Market Size in 2021:||USD 13.4 Billion|
|Forecast Period 2021-2030 CAGR:||20.2%|
|2030 Value Projection:||USD 54.1 Billion|
|Historical Data for:||2017-2020|
|No. of Pages:||200|
|Tables, Charts & Figures:||100|
|Segments covered:||By Type, By Indication, By Distribution Channel, By Region, By End-use|
|Companies Covered:||Adherium Limited, Aptar Group Inc. (Cohero Health Inc.), AstraZeneca, Inc., Cognita Labs, Llc., GlaxoSmithKline Plc, Novartis AG, OPKO Health Inc., Philip Morris International Inc. (Vectura Group Plc), ResMed Inc. (Propeller Health), Teva Pharmaceutical Industries Ltd|
|Pitfalls & Challenges:||COVID-19 Empact, Challenge, Future, Growth, & Analysis|
Get more details on this report -
Key Market Drivers
Rising cases of asthma to drive the market
The rise in the number of asthma patients is anticipated to the drive the global respiratory inhalers market growth over the predicted timeframe. For instance, as per the report published by The Global Asthma in 2018, currently there are 300 million people across the world who are suffering from asthma and this number is anticipated to reach 100 million by 2025. Furthermore, the increasing prevalence of Chronic Obstructive Pulmonary Disease (COPD) is also anticipated to contribute towards the market growth. For instance, Global Initiative for Chronic Obstruction Disease states that COPD is anticipated to led 4.5 million deaths across the world by the year 2030.
Increasing air pollution to propel the market growth
Within the upcoming years, it is predicted, the air pollution level is going to increase which is why more and more people will be prone to lung diseases which result in increasing demand for respiratory inhalers. For instance, Organisation for Economic Cooperation and Development estimated that by the year 2050, greenhouse gases emission is going to increase by around 50% due to the 70% increase in the emissions of carbon dioxide. Hence, the pollution level in different regions is going to increase and so does the number of patients.
Key Market Challenges
High cost associated with respiratory inhalers to restrain the market growth
Respiratory inhalers are extremely costly which become difficult for the patients of the developing nations to afford them which is hampering the overall growth of global respiratory inhalers market. Apart from this, the rise in the adoption of alternative treatments like subcutaneous injections and oral medicines which are easily available in the government hospitals and NGOs in the developing nations are restraining the market growth.
MDIs segment is dominating the market with the largest market share over the forecast period.
On the basis of type, the global respiratory inhalers market are segmented into dry powder inhalers and metered dose inhalers. Among these, the metered dose inhalers segment is dominating the market with the largest market share over the forecast period. The main reason behind the growth is they are easy to use and reliable in a short sprays of a fixed dose which are administered by the patients by inhaling. For instance, in September 2022, OzUK Limited and H&T Presspart , a UK based research laboratory has tied up with each other to introduce generic MDIs in the market for the customers of H&T.
COPD segment accounted the largest market share over the forecast period.
Based on the indication, the global respiratory inhalers market is bifurcated into asthma, Chronic Obstructive Pulmonary Disease (COPD), Others. Among these, the COPD segment holds the largest market share and is going to continue its dominance over the forecast period. As per the WHO, nearly 3.23 million fatalities has been registered due to COPD in the year 2019. The asthma segment on the other hand is witnessing significant growth owing the increasing number of hospitalization, especially in young children. WHO states that around 300 million people across the world are suffering from asthma and number is going to increase by 50% in every ten years.
Distribution Channel Insights
Hospital pharmacies is dominating the market with the largest market share over the forecast period.
On the basis of distribution channel, the global respiratory inhalers market is categorized into hospital pharmacies, online pharmacies, and retail pharmacies. Among these, the hospital pharmacies segment is dominating the market with the largest market share over the forecast period owing to the increasing geriatric population as well as increasing cases of CRDs which are playing the significant role for the growth of the market. The geriatric people are often admitted to hospitals for various chronic respiratory disease and they prefer purchasing medicines from hospital pharmacies.
End Use Insights
Hospitals segment is dominating the market with the largest market share over the forecast period.
On the basis of end use, the global respiratory inhalers market is segmented into hospitals, home care settings, and others. Among these, the hospitals segment is dominating the market and is going to continue its dominance over the forecast period. The expansion in the number of private-public partnerships, advancements in healthcare units and easy access to healthcare services are anticipated to contribute towards the growth of the market. The home care settings segment is anticipated to witness faster growth over the forecast period owing to the increasing cost of healthcare, many people prefer homecare settings.
North America is dominating the market with the largest market share over the forecast period.
Get more details on this report -
North America accounted the largest market share owing to the increasing prevalence of asthma and COPD in Canada and US. In September 2021, Adherium Limited which is key market players in remote monitoring and respiratory eHealth has made an announcement that the U.S. FDA 510 (k) has given an approval for its Halie Sensor.
Asia Pacific, on the other hand is anticipated to witness the fastest market growth over the forecast period owing the increasing number of elderly people and rising prevalence of CRDs, expansion in healthcare infrastructure, and lots of strategic initiatives taken by the government.
Recent Market Developments
- In August 2022, Adherium Limited has partnered with Trudell Medical Limited to treat COPD patients in the U.S.
List of Key Companies
- Adherium Limited
- Aptar Group Inc. (Cohero Health Inc.)
- AstraZeneca, Inc.
- Cognita Labs, Llc.
- GlaxoSmithKline Plc
- Novartis AG
- OPKO Health Inc.
- Philip Morris International Inc. (Vectura Group Plc)
- ResMed Inc. (Propeller Health)
- Teva Pharmaceutical Industries Ltd
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global Respiratory Inhalers Market based on the below-mentioned segments:
Respiratory Inhalers Market, Type Analysis
- Dry Powdered Inhalers
- Metered Dose Inhalers
Respiratory Inhalers Market, Indication Analysis
Respiratory Inhalers Market, Distribution Channel Analysis
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Respiratory Inhalers Market, End Use Analysis
- Homecare Settings
Respiratory Inhalers Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Frequently Asked Questions (FAQ)
1. What is the market size of Respiratory Inhalers Market?The global Respiratory Inhalers Market is expected to grow from USD 13.4 Billion in 2021 to USD 54.1 Billion by 2030, at a CAGR of 20.2% during the forecast period 2022-2030.
2. Who are the key market players of Respiratory Inhalers Market?Some of the key market players of Respiratory Inhalers Market are Adherium Limited, Aptar Group Inc. (Cohero Health Inc.), AstraZeneca, Inc., Cognita Labs, Llc., GlaxoSmithKline Plc, Novartis AG, OPKO Health Inc., Philip Morris International Inc. (Vectura Group Plc), ResMed Inc. (Propeller Health) and Teva Pharmaceutical Industries Ltd.
3. Which segment hold the largest market share?Hospital Pharmacies segment hold the largest market share is going to continue its dominance.
4. Which region is dominating the Respiratory Inhalers Market?North America is dominating the Respiratory Inhalers Market with the highest market share.
Need help to buy this report?